Retatrutide and Tirzepatide are both incretin-based research peptides, but they are not the same class of molecule. This comparison outlines the differences that matter for research applications.
Receptor profiles
Tirzepatide is a dual agonist, activating the GIP and GLP-1 receptors. Retatrutide is a triple agonist, adding glucagon-receptor activity to those two. That extra axis is the central reason researchers study them side by side: it allows comparison of dual- versus triple-receptor pharmacology in the same experimental system.
Structural differences
Both are synthetic peptides with engineered modifications for stability and receptor selectivity, but their amino acid sequences and receptor-binding profiles differ. Retatrutide’s design balances activity across three receptors, whereas Tirzepatide is tuned for two. These structural differences underpin their distinct receptor signatures.
Relative potency in research contexts
Relative potency depends entirely on the receptor and assay in question, so meaningful comparison requires controlled, in-vitro conditions and well-characterised material. This is exactly why batch purity and identity verification are so important — comparing two compounds is only valid if you know each is what it claims to be.
Relevant studies
Both compounds appear in the metabolic-research literature, with Retatrutide attracting attention as a newer triple-agonist entrant. Researchers designing comparative work should consult primary sources for assay-specific data. See our summary of Retatrutide Phase 3 results, and for the single-agonist end of the spectrum, Retatrutide vs Semaglutide.
Sourcing both for comparison
Pepreta supplies both as HPLC-verified, lyophilised research material with batch COAs. For background on Retatrutide specifically, see our peptide overview and triple-agonist explainer. Both are research use only.